Multiple Sclerosis Journal最新文献_第4页

Erratum to "Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis" Multiple Sclerosis Journal; 2024: 30(8); 1086-1088. DOI: 10.1177/13524585241260564. 多发性硬化症杂志》；2024：30(8)；1086-1088。DOI: 10.1177/13524585241260564.

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2024-10-22 DOI: 10.1177/13524585241290986

引用次数: 0

Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis. 多发性硬化症患者改用封存性疾病修饰疗法后外周免疫系统的长期改变。

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2024-10-07 DOI: 10.1177/13524585241284846

Marco Vercellino, Stella Marasciulo, Emanuela Ricotti, Anna Rolando, Chiara Bosa, Paola Garelli, Virginia Gallina, Giovanna Vaula, Andrea Calvo, Paola Cavalla

{"title":"Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis.","authors":"Marco Vercellino, Stella Marasciulo, Emanuela Ricotti, Anna Rolando, Chiara Bosa, Paola Garelli, Virginia Gallina, Giovanna Vaula, Andrea Calvo, Paola Cavalla","doi":"10.1177/13524585241284846","DOIUrl":"https://doi.org/10.1177/13524585241284846","url":null,"abstract":"Background: Scarce data are available on the long-term immunological effects of multiple sclerosis (MS) disease-modifying treatments (DMTs).Objectives: This study aimed to investigate the long-term modifications of the peripheral immune repertoire on interruption of a sequestering DMT (natalizumab, fingolimod) and switch to another high-efficacy DMT.Methods: Lymphocyte subpopulations were assessed, every 6 months up to 48 months, in patients switched from fingolimod or natalizumab to ocrelizumab, and in patients switched from fingolimod to natalizumab, compared to patients switched to ocrelizumab or natalizumab from a moderate-efficacy DMT and to naive patients.Results: We included 389 MS patients (200 ocrelizumab and 189 natalizumab). After adjusting for baseline variables, patients switched from fingolimod to ocrelizumab showed lower CD3 + and CD4 + lymphocytes up to 48 months after switch (with lower percentage of naive CD4 +), and increased odds of total, CD3+, CD4+ lymphopenia. Patients switched from natalizumab to ocrelizumab showed higher CD3 + lymphocytes up to 36 months after switch, and higher CD4+, CD8+ lymphocytes up to 24 months. The frequency of infections was not influenced by previous treatment.Conclusions: A long-term persistence of the residual effects of the exposure to sequestering DMTs (fingolimod and less natalizumab) on the peripheral immune repertoire was observed after switching to another high-efficacy DMT.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"13524585241284846"},"PeriodicalIF":4.8,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The current state of diversity, equity, and inclusion in multiple sclerosis research, clinical trials, and workforce. 多发性硬化症研究、临床试验和劳动力的多样性、公平性和包容性现状。

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2024-10-01 Epub Date: 2024-10-08 DOI: 10.1177/13524585241286988

Lilyana Amezcua, Roy H Hamilton, Olga Ciccarelli

引用次数: 0

Time to move past typical syndromes in the diagnosis of multiple sclerosis. 在诊断多发性硬化症的过程中，是时候摆脱典型综合征的束缚了。

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2024-10-01 Epub Date: 2024-05-15 DOI: 10.1177/13524585241253519

Christine Lebrun-Frenay, Darin T Okuda

引用次数: 0

Subtypes and location of (juxta)cortical lesions relate to cognitive dysfunction in people with multiple sclerosis. 多发性硬化症患者认知功能障碍与（并）皮质病变的亚型和位置有关。

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2024-10-01 Epub Date: 2024-06-13 DOI: 10.1177/13524585241260968

Eva A Krijnen, Rose-Marie Kouwenhoven, Samantha Noteboom, Frederik Barkhof, Bernard Mj Uitdehaag, Eric C Klawiter, Martijn D Steenwijk, Menno M Schoonheim, Ismail Koubiyr

引用次数: 0

Discrepancies in the results reported for multiple sclerosis clinical trials: A comparison between ClinicalTrials.gov and peer-reviewed journals. 多发性硬化症临床试验结果报告中的差异：临床试验网站（ClinicalTrials.gov）与同行评审期刊的比较。

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2024-10-01 Epub Date: 2024-08-27 DOI: 10.1177/13524585241273089

Alejandro Rivero-de-Aguilar, Mónica Pérez-Ríos, Marta Mascareñas-García, Alberto Ruano-Raviña, Joseph S Ross, Beatriz Casal-Acción, Leonor Varela-Lema

{"title":"Discrepancies in the results reported for multiple sclerosis clinical trials: A comparison between ClinicalTrials.gov and peer-reviewed journals.","authors":"Alejandro Rivero-de-Aguilar, Mónica Pérez-Ríos, Marta Mascareñas-García, Alberto Ruano-Raviña, Joseph S Ross, Beatriz Casal-Acción, Leonor Varela-Lema","doi":"10.1177/13524585241273089","DOIUrl":"10.1177/13524585241273089","url":null,"abstract":"Objective: We aimed to compare the results of phase III and IV clinical trials examining drugs to treat multiple sclerosis (MS) registered at ClinicalTrials.gov to those published in peer-reviewed journals.Methods: After identifying trials registered at ClinicalTrials.gov, consecutive searches were conducted in PubMed, EMBASE and Google Scholar for matching publications. Information regarding participants and efficacy and safety results was extracted and compared. The degree of consistency was classified as 'concordant', 'discrepant' or 'not comparable'. The Kaplan-Meier method was used to model time to reporting.Results: In total, 65 trials were appraised. The median time from completion to reporting was shorter for ClinicalTrials.gov (16.4 vs 27.3 months; p = 0.010). Information availability was generally higher in journals except for serious adverse events (SAEs) (86.2% vs 100.0%, p = 0.029) and their description (78.2% vs 100.0%, p < 0.001). However, 45 trials had at least one reporting discrepancy (69.2%). Three studies omitted one or more primary outcomes in the matching journal publication. Regarding safety results, the lowest consistencies were found for causes of death (60.0%) and description of SAEs (27.9%).Conclusion: Consulting both ClinicalTrials.gov and journals increases the accessibility to MS clinical trial results. Some data were frequently missing or disagreed between sources, raising concerns about transparency and generalizability of results.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1514-1524"},"PeriodicalIF":4.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cognitive progression independent of relapse in multiple sclerosis. 多发性硬化症患者的认知进展与复发无关。

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2024-10-01 Epub Date: 2024-08-28 DOI: 10.1177/13524585241256540

Tom A Fuchs, Menno M Schoonheim, Robert Zivadinov, Michael G Dwyer, Elisa Colato, Zachary Weinstock, Bianca Weinstock-Guttman, Eva Mm Strijbis, Ralph Hb Benedict

{"title":"Cognitive progression independent of relapse in multiple sclerosis.","authors":"Tom A Fuchs, Menno M Schoonheim, Robert Zivadinov, Michael G Dwyer, Elisa Colato, Zachary Weinstock, Bianca Weinstock-Guttman, Eva Mm Strijbis, Ralph Hb Benedict","doi":"10.1177/13524585241256540","DOIUrl":"10.1177/13524585241256540","url":null,"abstract":"Background: Substantial physical-disability worsening in relapsing-remitting multiple sclerosis (RRMS) occurs outside of clinically recorded relapse. This phenomenon, termed progression independent of relapse activity (PIRA), is yet to be established for cognitive decline.Methods: Retrospective analysis of RRMS patients. Cognitive decline was defined using reliable-change-index cut-offs for each test (Symbol Digit Modalities Test, Brief Visuospatial Memory Test-Revised, California Verbal Learning Test-II). Decline was classified as PIRA if the following conditions were met: no relapse observed between assessments nor within 9 months of cognitive decline.Results: The study sample (n = 336) was 80.7% female with a mean (standard deviation (SD)) age, disease duration, and observation period of 43.1 (9.5), 10.8 (8.4), and 8.1 (3.1) years, respectively. A total of 169 (50.3%) subjects were cognitively impaired at baseline relative to age-, sex-, and education-matched HCs. Within subjects who experienced cognitive decline (n = 167), 89% experienced cognitive PIRA. A total of 141 (68.1%) cognitive decline events were observed independent of EDSS worsening. Cognitive PIRA was more likely to be observed with increased assessments (p < 0.001) and lower assessment density (p < 0.001), accounting for baseline clinical factors.Conclusion: These results establish the concept of cognitive PIRA and further our understanding of progressive cognitive decline in RRMS.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1468-1478"},"PeriodicalIF":4.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline. 多发性硬化症的进展与复发活动无关：考虑认知能力下降的时间

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2024-10-01 Epub Date: 2024-08-28 DOI: 10.1177/13524585241273037

Carmen Tur, Emilio Portaccio

引用次数: 0

Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model. 使用多态模型预测多发性硬化症恶化和好转的因素。

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2024-10-01 Epub Date: 2024-09-28 DOI: 10.1177/13524585241275471

Alex Ocampo, Farhad Hatami, Jelena Čuklina, Gordon Graham, Habib Ganjgahi, Yang Sun, Wendy Su, Marie-Catherine Mousseau, Stephen Gardiner, Samantha C Pendleton, Piet Aarden, Bernd C Kieseier, Douglas L Arnold, Robert A Bermel, Dieter A Häring, Thomas E Nichols, Heinz Wiendl

{"title":"Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model.","authors":"Alex Ocampo, Farhad Hatami, Jelena Čuklina, Gordon Graham, Habib Ganjgahi, Yang Sun, Wendy Su, Marie-Catherine Mousseau, Stephen Gardiner, Samantha C Pendleton, Piet Aarden, Bernd C Kieseier, Douglas L Arnold, Robert A Bermel, Dieter A Häring, Thomas E Nichols, Heinz Wiendl","doi":"10.1177/13524585241275471","DOIUrl":"10.1177/13524585241275471","url":null,"abstract":"Background: The long-term disease trajectory of people living with multiple sclerosis (MS) can be improved by initiating efficacious treatment early. More quantitative evidence is needed on factors that affect a patient's risk of disability worsening or possibility of improvement to inform timely treatment decisions.Methods: We developed a multistate model to quantify the influence of demographic, clinical, and imaging factors on disability worsening and disability improvement simultaneously across the disability spectrum as measured by the Expanded Disability Status Scale (EDSS). We used clinical trial data from the Novartis-Oxford MS database including ~130,000 EDSS assessments from ~8000 patients, spanning all MS phenotypes.Results: Higher brain volume was positively associated with disability improvement at all disability levels (hazard ratio (HR) = 1.09-1.19; 95% credible interval (CI) = 1.02-1.27). Higher T2 lesion volume was negatively associated with disability improvement up to EDSS 6 (HR = 0.80-0.89; 95% CI = 0.75-0.94). Older age, time since first symptoms, and the number of relapses in the past year were confirmed as predictors of future disability worsening.Conclusions: Brain damage was identified as the most consistent factor limiting the patient's probability for improvements from the earliest stages and across the whole course of MS. Protecting brain integrity early in MS should have greater weight in clinical decision-making.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1455-1467"},"PeriodicalIF":4.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiple sclerosis presenting with paroxysmal symptoms: Patients at the limitations of current diagnostic criteria. 出现阵发性症状的多发性硬化症：受现行诊断标准限制的患者。

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2024-10-01 Epub Date: 2024-05-15 DOI: 10.1177/13524585241253513

Karl D Heward, Chantal Roy-Hewitson, Andrew J Solomon

引用次数: 0